Diligence memo · auto-generated · as of July 2, 2026

Greenlight Biosciences Inc.

Greenlight Biosciences Inc. has raised $179M over 5 rounds; too few niche peers to rank its valuation yet.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Greenlight Biosciences Inc. operates in Biotech / Pharma, based in Medford.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Greenlight Biosciences Inc. has raised $179M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $103M on 2020-06-15.

Most recent recorded round closed around 2020-06-15.

Valuation (modeled)modeled

Provath models Greenlight Biosciences Inc. at approximately $3.9B (range $477M–$8.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Too few comparable companies in this niche to rank the valuation fairly yet.

Financing rhythm & timingmixed

Historic cadence: a new round about every 17 months.

Last raise 6.0 yr ago; this sector typically re-raises about every 15 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 2.6× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 98% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 100% of those peers.

Peoplefiled

22 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.